Deciphering the contribution of 5'-tiRNA- Lys-CTT as an emerging early diagnostic biomarker for hepatocellular carcinoma
Abstract
Hepatocellular carcinoma (HCC) remains a leading cause of cancer mortality worldwide, with early detection critical for improving survival rates. Late-stage diagnosis contributes to dismal prognosis. Current surveillance relies on ultrasonography and serum alpha-fetoprotein (AFP), yet AFP exhibits limited sensitivity and specificity for early HCC. Emerging non-coding RNAs, particularly tRNA-derived small RNAs (tsRNAs), offer stable, detectable alternatives for liquid biopsy. Among these, 5′-tiRNA-Lys-CTT, a 5′-tRNA half derived from tRNA-Lys-CTT, has shown promise. This commentary explores the potential of 5′-tiRNA-Lys-CTT, a tRNA-derived small RNA (tsRNA), as an emerging biomarker for early HCC detection. It integrates biology, diagnostic performance along with recent advancements in tsRNA research for Hepatocellular carcinoma (HCC), and discusses potential clinical applications for enhanced early detection and personalized therapy. Ultimately, 5′-tiRNA-Lys-CTT represents a promising avenue for liquid biopsy-based screening, potentially revolutionizing HCC management.
Read the paper
Related studies
- Regulation of nucleolus assembly by non-coding RNA polymerase II transcripts
- For a Healthy Histone Code, a Little SUMO in the Tail Keeps the Acetyl Away
- Discovering a binary CTCF code with a little help from BORIS
- Article Commentary: Stabilizing the Code–-Methods to Preserve RNA Prove Their Worth
- Foreword to the Special Issue for the RINTC (The Implicit Seismic Risk of Code-Conforming Structures) Project
- Commentary: Promoting Health and Well-being in Pediatric Primary Care Settings: Using Health and Behavior Codes at Routine Well-child Visits
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.